Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Richard Close maintains a Buy rating on Teladoc Health (TDOC) but lowers the price target from $28 to $25.

April 26, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Teladoc Health but lowers the price target from $28 to $25.
The adjustment in price target by Canaccord Genuity reflects a revised valuation perspective, yet the maintenance of a Buy rating suggests continued confidence in the company's fundamentals. This could lead to mixed short-term market reactions, balancing between the positive outlook and the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100